183 related articles for article (PubMed ID: 15756009)
21. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Jaeger J; Koczan D; Thiesen HJ; Ibrahim SM; Gross G; Spang R; Kunz M
Clin Cancer Res; 2007 Feb; 13(3):806-15. PubMed ID: 17289871
[TBL] [Abstract][Full Text] [Related]
22. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas.
Onken MD; Lin AY; Worley LA; Folberg R; Harbour JW
Am J Ophthalmol; 2005 Oct; 140(4):748-9. PubMed ID: 16226537
[TBL] [Abstract][Full Text] [Related]
23. Cytogenetics of uveal melanoma: a 7-year clinical experience.
Damato B; Duke C; Coupland SE; Hiscott P; Smith PA; Campbell I; Douglas A; Howard P
Ophthalmology; 2007 Oct; 114(10):1925-31. PubMed ID: 17719643
[TBL] [Abstract][Full Text] [Related]
24. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma.
Maat W; Ly LV; Jordanova ES; de Wolff-Rouendaal D; Schalij-Delfos NE; Jager MJ
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):505-10. PubMed ID: 18234992
[TBL] [Abstract][Full Text] [Related]
25. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
26. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients.
Laurent C; Valet F; Planque N; Silveri L; Maacha S; Anezo O; Hupe P; Plancher C; Reyes C; Albaud B; Rapinat A; Gentien D; Couturier J; Sastre-Garau X; Desjardins L; Thiery JP; Roman-Roman S; Asselain B; Barillot E; Piperno-Neumann S; Saule S
Cancer Res; 2011 Feb; 71(3):666-74. PubMed ID: 21135111
[TBL] [Abstract][Full Text] [Related]
27. The miRNA expression profile of the uveal melanoma.
Yang C; Wei W
Sci China Life Sci; 2011 Apr; 54(4):351-8. PubMed ID: 21509659
[TBL] [Abstract][Full Text] [Related]
28. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
[TBL] [Abstract][Full Text] [Related]
29. Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival.
Lake SL; Damato BE; Kalirai H; Dodson AR; Taktak AF; Lloyd BH; Coupland SE
Am J Pathol; 2013 Mar; 182(3):678-87. PubMed ID: 23357503
[TBL] [Abstract][Full Text] [Related]
30. Expression of epidermal growth factor receptor: risk factor in uveal melanoma.
Hurks HM; Metzelaar-Blok JA; Barthen ER; Zwinderman AH; De Wolff-Rouendaal D; Keunen JE; Jager MJ
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2023-7. PubMed ID: 10892838
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
32. Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization.
Naus NC; Verhoeven AC; van Drunen E; Slater R; Mooy CM; Paridaens DA; Luyten GP; de Klein A
Clin Cancer Res; 2002 Feb; 8(2):534-9. PubMed ID: 11839674
[TBL] [Abstract][Full Text] [Related]
33. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
Maat W; Beiboer SH; Jager MJ; Luyten GP; Gruis NA; van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1291-8. PubMed ID: 18385040
[TBL] [Abstract][Full Text] [Related]
35. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
Rangel J; Torabian S; Shaikh L; Nosrati M; Baehner FL; Haqq C; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
J Clin Oncol; 2006 Oct; 24(28):4565-9. PubMed ID: 17008696
[TBL] [Abstract][Full Text] [Related]
37. Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers.
Hendrix MJ; Seftor EA; Seftor RE; Gardner LM; Boldt HC; Meyer M; Pe'er J; Folberg R
Lab Invest; 1998 Feb; 78(2):153-63. PubMed ID: 9484713
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
39. Clinical and cytogenetic analyses in uveal melanoma.
Kilic E; van Gils W; Lodder E; Beverloo HB; van Til ME; Mooy CM; Paridaens D; de Klein A; Luyten GP
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3703-7. PubMed ID: 16936076
[TBL] [Abstract][Full Text] [Related]
40. Bone morphogenetic protein 7 inhibits tumor growth of human uveal melanoma in vivo.
Notting I; Buijs J; Mintardjo R; van der Horst G; Vukicevic S; Lowik C; Schalij-Delfos N; Keunen J; van der Pluijm G
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4882-9. PubMed ID: 17962434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
